{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-022877","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.894014+00:00","generated_at":"2026-05-18T05:56:21.450105+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer","bullets":["DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.","Pooled cohorts 6-9 (n=12) showed sustained BP reductions at 5 min, 30 min, and 24 hours (p≤0.0031).","No placental transfer; no serious TEAEs; mild nausea (14%), headache (11%), flushing (4%); no discontinuations.","Uterine artery pulsatility index reduced 13.2% (p=0.0003), indicating improved placental perfusion.","Study to proceed with dose expansion (Part 1b) and initiate fetal growth restriction cohort (Part 3)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-022877","json":"https://secwatch.observer/filing/0001437749-25-022877.json","markdown":"https://secwatch.observer/filing/0001437749-25-022877.md","text":"https://secwatch.observer/filing/0001437749-25-022877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/0001437749-25-022877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/dmtp20250716_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:56:21.450105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}